Baseline characteristics of final propensity-score matched cohort
| . | Statin users (cases) n = 657 . | Nonstatin users (controls) n = 1971 . | P value . |
|---|---|---|---|
| Age (mean) | 79.4 (74-84) | 80.3 (75-86) | .006 |
| Gender | <.001 | ||
| Male | 54.6% | 46.7% | |
| Female | 45.4% | 53.3% | |
| Race | .959 | ||
| Caucasian | 88.7% | 88.3% | |
| African-American | 5.8% | 5.9% | |
| Other | 5.5% | 5.7% | |
| Ethnicity | .683 | ||
| Hispanic or Latino | 6.2% | 6.7% | |
| Non-Hispanic or Latino | 93.8% | 93.3% | |
| Urban-rural | .228 | ||
| Metro | 87.5% | 85.6% | |
| Nonmetro | 12.5% | 14.4% | |
| Medicaid | .059 | ||
| Enrolled | 23.7% | 27.5% | |
| Not enrolled | 76.3% | 72.5% | |
| SMMRS | .466 | ||
| Low-risk | 26.9% | 25.0% | |
| Intermediate1-risk | 27.6% | 28.1% | |
| Intermediate2-risk | 25.7% | 24.6% | |
| High-risk | 19.8% | 22.4% | |
| Blood transfusions within 3 mo of diagnosis | 50% | 52% | .417 |
| Treatment within 6 mo of diagnosis | |||
| For lower-risk MDS∗ | 56.6% | 57.5% | .682 |
| For higher-risk MDS∗ | 21.8% | 21.1% | .700 |
| Cardiovascular comorbidities | |||
| Hyperlipidemia | 88.7% | 89.0% | .858 |
| Hypertension | 91.8% | 91.8% | .967 |
| Myocardial infarction | 14.6% | 12.0% | .084 |
| Peripheral vascular disease | 37.1% | 38.0% | .693 |
| Cerebrovascular disease/stroke | 34.7% | 30.6% | .050 |
| Diabetes | 49.2% | 48.5% | .770 |
| . | Statin users (cases) n = 657 . | Nonstatin users (controls) n = 1971 . | P value . |
|---|---|---|---|
| Age (mean) | 79.4 (74-84) | 80.3 (75-86) | .006 |
| Gender | <.001 | ||
| Male | 54.6% | 46.7% | |
| Female | 45.4% | 53.3% | |
| Race | .959 | ||
| Caucasian | 88.7% | 88.3% | |
| African-American | 5.8% | 5.9% | |
| Other | 5.5% | 5.7% | |
| Ethnicity | .683 | ||
| Hispanic or Latino | 6.2% | 6.7% | |
| Non-Hispanic or Latino | 93.8% | 93.3% | |
| Urban-rural | .228 | ||
| Metro | 87.5% | 85.6% | |
| Nonmetro | 12.5% | 14.4% | |
| Medicaid | .059 | ||
| Enrolled | 23.7% | 27.5% | |
| Not enrolled | 76.3% | 72.5% | |
| SMMRS | .466 | ||
| Low-risk | 26.9% | 25.0% | |
| Intermediate1-risk | 27.6% | 28.1% | |
| Intermediate2-risk | 25.7% | 24.6% | |
| High-risk | 19.8% | 22.4% | |
| Blood transfusions within 3 mo of diagnosis | 50% | 52% | .417 |
| Treatment within 6 mo of diagnosis | |||
| For lower-risk MDS∗ | 56.6% | 57.5% | .682 |
| For higher-risk MDS∗ | 21.8% | 21.1% | .700 |
| Cardiovascular comorbidities | |||
| Hyperlipidemia | 88.7% | 89.0% | .858 |
| Hypertension | 91.8% | 91.8% | .967 |
| Myocardial infarction | 14.6% | 12.0% | .084 |
| Peripheral vascular disease | 37.1% | 38.0% | .693 |
| Cerebrovascular disease/stroke | 34.7% | 30.6% | .050 |
| Diabetes | 49.2% | 48.5% | .770 |
Data represent baseline characteristics of patients with MDS, stratified by statin use.
Treatments for lower-risk MDS included blood transfusions, erythropoietin stimulating agents and lenalidomide, treatments for higher-risk MDS included hypomethylating agents and stem cell transplant.